CHIARA TAMMARO

Dr. CHIARA TAMMARO

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Nature
Verified
Journal Article
Open access
APAlexandra S. Probst
Alexandra S. Probst
DPDouglas G. Paton
Douglas G. Paton
FAFederico Appetecchia
Federico Appetecchia
SBSelina Bopp
Selina Bopp
KAKelsey L. Adams
Kelsey L. Adams
FCFlaminia Catteruccia
Flaminia Catteruccia
The decline in malaria deaths has recently stalled owing to several factors, including the widespread resistance of Anopheles vectors to the insecticides used in long-lasting insecticide-treated nets (LLINs)1,2. One way to mitigate insecticide resistance is to directly kill parasites during their mosquito-stage of development by incorporating antiparasitic compounds into LLINs. This strategy can prevent onward parasite transmission even when insecticides lose efficacy3,4. Here, we performed an in vivo screen of compounds against the mosquito stages of Plasmodium falciparum development. Of the 81 compounds tested, which spanned 28 distinct modes of action, 22 were active against early parasite stages in the mosquito midgut lumen, which in turn prevented establishment of infection. Medicinal chemistry was then used to improve antiparasitic activity of the top hits from the screen. We generated several endochin-like quinolones (ELQs) that inhibited the P. falciparum cytochrome bc 1 complex (CytB). Two lead compounds that targeted separate sites in CytB (Qo and Qi) showed potent, long-lasting and stable activity when incorporated and/or extruded into bed net-like polyethylene films. ELQ activity was fully preserved in insecticide-resistant mosquitoes, and parasites resistant to these compounds had impaired development at the mosquito stage. These data demonstrate the promise of incorporating ELQ compounds into LLINs to counteract insecticide resistance and to reduce malaria transmission.

29 January 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
CTCHIARA TAMMARO
CHIARA TAMMARO
MGMichela Guida
Michela Guida
Federico AppetecchiaFederico Appetecchia
Federico Appetecchia
Mariangela BiavaMariangela Biava
Mariangela Biava
SCSara Consalvi
Sara Consalvi
GPGiovanna Poce
Giovanna Poce
Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.

28 May 2024 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MGMichela Guida
Michela Guida
CTCHIARA TAMMARO
CHIARA TAMMARO
MQMiriana Quaranta
Miriana Quaranta
BSBenedetta Salvucci
Benedetta Salvucci
Mariangela BiavaMariangela Biava
Mariangela Biava
SCSara Consalvi
Sara Consalvi
According to the latest World Health Organization (WHO) report, an estimated 10.6 million people were diagnosed with tuberculosis (TB) in 2022, and 1.30 million died. A major concern is the emergence of multi-drug-resistant (MDR) and extensively drug-resistant (XDR) strains, fueled by the length of anti-TB treatment and HIV comorbidity. Innovative anti-TB agents acting with new modes of action are the only solution to counteract the spread of resistant infections. To escape starvation and survive inside macrophages, Mtb has evolved to become independent of the host by synthesizing its own amino acids. Therefore, targeting amino acid biosynthesis could subvert the ability of the mycobacterium to evade the host immune system, providing innovative avenues for drug discovery. The aim of this review is to give an overview of the most recent progress in the discovery of amino acid biosynthesis inhibitors. Among the hits discovered over the past five years, tryptophan (Trp) inhibitors stand out as the most advanced and have significantly contributed to demonstrating the feasibility of this approach for future TB drug discovery. Future efforts should be directed at prioritizing the chemical optimization of these hits to enrich the TB drug pipeline with high-quality leads.

18 November 2024 in Expert Opinion on Therapeutic Patents
Verified
Journal Article
Closed access
SBSalvucci Benedetta
Salvucci Benedetta
FVFrancesco Vallini
Francesco Vallini
MGMichela Guida
Michela Guida
CTCHIARA TAMMARO
CHIARA TAMMARO
MBMariangela Biava
Mariangela Biava
GPGiovanna Poce
Giovanna Poce
IntroductionTuberculosis (TB) remains a major global health issue, causing around 10 million new cases and 1.3 million deaths in 2022. The challenge is compounded by multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB strains, and co-infection with HIV.Areas coveredThe present review examines significant patent literature on TB chemotherapeutics from September 2021 to the present using the following databases, reaxys, google patent and espacenet. Only patents reporting compounds with a minimum inhibitory concentration (MIC) on whole Mycobacterium tuberculosis cells of <= 5 mu M were selected for review.Expert opinionThe fight against TB is advancing with the development of promising new compounds due to the challenge of drug-resistant strains. Notable among those reviewed in this paper are the benzothiazinones, showing high efficacy against both drug-sensitive and resistant TB strains. Additionally, Q203 analogues, demonstrate strong antitubercular activity, good microsomal stability, and favorable safety profiles. Finally, LysRS inhibitors also show significant promise in vivo models. These advancements underscore the importance of novel targets and innovative strategies in developing effective, resistance-resistant TB treatments.

13 October 2025 in VeriXiv
Verified
Preprint
Open access
LKLutete Peguy Khonde
Lutete Peguy Khonde
NPNashied Peton
Nashied Peton
KMKeabetswe Masike
Keabetswe Masike
TVTanya Valentine
Tanya Valentine
FZFrank Zindo
Frank Zindo
KCKelly Chibale
Kelly Chibale